Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide.

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits.

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, overtaking GSK's widely used antibiotic Augmentin, as demand surges in the world's most populous nation.

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

The White House announced reduced pricing for the popular weight-loss drugs made by Eli Lilly and Novo Nordisk.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.